Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Pilot Study of Chlorpromazine Hydrochloride 25 mg Tablets
NCT02943213Phase 1Completed
- Sponsor
- Cycle Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Aminazin in schizophrenia, psychotic disorders, nausea ((none)) and 5 more, sponsored by Cycle Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration Versus Time Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Nov 2016; status: completed.
02
Drugs
Aminazin
03
Conditions
schizophreniapsychotic disordersnausea ((none))VomitingTetanus
Beyond the preview
Go deeper on NCT02943213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943213.